Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Average Rating of "Moderate Buy" by Brokerages

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Get Free Report) has been given an average rating of "Moderate Buy" by the six research firms that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $4.50.

A number of research analysts have recently weighed in on the company. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a research report on Monday, April 7th. Royal Bank Of Canada reaffirmed a "sector perform" rating and set a $2.00 price objective on shares of Sangamo Therapeutics in a research report on Tuesday, March 18th. Barclays lowered their price objective on Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating on the stock in a research report on Wednesday, May 14th. Finally, Wall Street Zen cut Sangamo Therapeutics from a "hold" rating to a "sell" rating in a research report on Friday, May 30th.

Sangamo Therapeutics Stock Down 5.6%

Sangamo Therapeutics stock opened at $0.43 on Tuesday. The business has a 50-day simple moving average of $0.58 and a two-hundred day simple moving average of $1.00. The company has a market cap of $100.73 million, a P/E ratio of -1.11 and a beta of 1.20. Sangamo Therapeutics has a 52-week low of $0.30 and a 52-week high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.03). The firm had revenue of $6.44 million for the quarter, compared to the consensus estimate of $7.90 million. Sangamo Therapeutics had a negative net margin of 124.61% and a negative return on equity of 345.98%. Research analysts anticipate that Sangamo Therapeutics will post -0.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in SGMO. E Fund Management Co. Ltd. purchased a new stake in shares of Sangamo Therapeutics during the 4th quarter worth approximately $25,000. JPMorgan Chase & Co. raised its holdings in shares of Sangamo Therapeutics by 679.5% during the 4th quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 21,793 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Sangamo Therapeutics by 2,319.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 26,078 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 25,000 shares in the last quarter. SBI Securities Co. Ltd. purchased a new stake in shares of Sangamo Therapeutics during the 4th quarter worth approximately $28,000. Finally, Captrust Financial Advisors purchased a new stake in shares of Sangamo Therapeutics during the 4th quarter worth approximately $30,000. 56.93% of the stock is currently owned by institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.